Scythian Biosciences Appoints Chief Medical Officer

Scythian Biosciences (TSXV:SCYB; OTCQB:SCCYF) announced the appointment of Professor Michael Barnes as the new chief medical officer for the company.

As quoted in the press release:

Professor Barnes MD FRCP is considered to be a leading world authority in neurological rehabilitation and has emerged as an influential voice in medical cannabis policy in Europe. Professor Barnes appointment as Scythian’s Chief Medical Officer aligns with Scythian’s goal of providing patients access to alternative treatment with pharmaceutical grade medical cannabis.

“Professor Barnes is a strong advocate of expanding medical cannabis use and is a respected global leader in the field of neuroscience,” said Vic Neufeld, a member of Scythian’s Board of Directors. “His powerful voice brings added credibility to Scythian’s mission to make safe and precisely dosed medical cannabis accessible to a growing number of patients in need.”

In line with Scythian’s ongoing efforts to develop cannabis-based therapies, Professor Barnes played a critical role in the development of Sativex, a proprietary product developed by GW Pharmaceuticals. Sativex is an oromucosal spray of formulated sativa plant extract for the treatment of spasticity due to multiple sclerosis.

Click here to read the full press release.

Source: globenewswire.com